COMP <GO>

REVB vs PPCB // OPTIONS IMPLIED MOVE & PUT/CALL SKEW

Revelation Biosciences Inc. (NASDAQ) VS. Propanc Biopharma Inc. (NASDAQ) • 15-METRIC TALLY: REVB 2 — PPCB 1

■ METRIC PARITY

LAST: $4.03 (+7.47%) • MKT CAP: $2.1M

options-implied-move

—

LAST: $1.84 (-12.80%) • MKT CAP: $2.2M

options-implied-move

—

15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (REVB VS. PPCB) EMERALD CELL = QUANTITATIVE EDGE

INSTITUTIONAL METRIC	REVB	PPCB	SPREAD (A - B)	ADVANTAGE	DEDICATED URL
Gross Profit Margin	—	—	—	TIE	/gross-margins <GO>
Return on Invested Capital (ROIC)	-35.00%	-35.00%	0.00	TIE	/roic <GO>
EV/EBITDA & P/E Valuation	—	—	—	TIE	/valuation <GO>
Free Cash Flow Yield	—	-18.59%	—	TIE	/fcf-yield <GO>
Operating Margin	—	—	—	TIE	/operating-margins <GO>
Net Profit Margin	—	—	—	TIE	/net-margins <GO>
Revenue Growth (YoY)	—	—	—	TIE	/revenue-growth <GO>
Dividend Yield & FCF Payout Safety	0.00%	0.00%	0.00	TIE	/dividend-safety <GO>
Altman Z-Score & Debt/Equity	—	—	—	TIE	/balance-sheet <GO>
Piotroski F-Score Quality	3/9	2/9	+1.00	REVB	/piotroski-score <GO>
Options Implied Move & Put/Call Skew ACTIVE	—	—	—	TIE	/options-implied-move <GO>
RSI-14 & 200D SMA Momentum	36.4	26.2	+10.20	REVB	/rsi-technicals <GO>
10Y Yield & FRED Macro Beta	—	—	—	TIE	/macro-sensitivity <GO>
Forward P/E Multiple	—	—	—	TIE	/forward-pe <GO>
Enterprise Scale & Market Cap	$2.1M	$2.2M	-$45.9K	PPCB	/market-cap <GO>

5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY

FISCAL YEAR	REVB REV	PPCB REV	REVB GROSS %	PPCB GROSS %	REVB FCF	PPCB FCF
FY 2025	$0	$0	—	—	-$8.3M	-$405.2K
FY 2024	$0	$0	—	—	-$18.3M	-$935.1K
FY 2023	$0	$0	—	—	-$7.3M	-$1.1M

FRED MACRO REGIME CORRELATION COMPARISON PEARSON r

REVB // BETA —

PPCB // BETA —